Intralinks 2013 Global Investigator Site Survey: Findings Highlight Need to Access Studies Across Multiple Sponsors through a Single Clinical Portal
NEW YORK, April 23, 2013 /PRNewswire/ -- Intralinks® Holdings, Inc. (NYSE: IL), a leading, global SaaS provider of inter-enterprise content management and collaboration solutions, today announced the results of the 2013 Intralinks Global Investigator Site Survey. The survey looked at how clinical investigator sites currently perceive clinical web portals. The findings revealed that 80% of respondents agreed that a single web portal with one login to access studies across multiple sponsors would be very valuable.
Investigator sites typically manage a significant number of studies, collaborating with numerous organizations using diverse technologies:
- 88% of respondents report accessing three or more clinical web portals
- 53% reported accessing six or more clinical web portals
The need to log into many portals makes it difficult to prioritize and manage tasks as they span trials. Based on the results of the 2013 Intralinks Global Investigator Site Survey, it is clear that investigator sites and study sponsors are looking for an integrated view of operational data that does not require opening multiple applications. In addition, investigator sites and sponsors are interested in being able to compare information across multiple trials, including patient enrollment timelines and study activation or start-up time, as the ability to quickly view information across studies would enable investigator sites and study sponsors to have a more intuitive understanding of study statuses, ultimately helping speed time-to-market.
Investigator sites and study sponsors were specific in what is most important to them in a clinical trial portal. They most wanted to see:
- Study/regulatory documents
- Study announcements/changes
- Training documents
- Query status
- Study timeline
- Patient recruitment information
These findings highlight the need for a single portal built on multi-tenant cloud architecture with simplified integration to multiple clinical applications from multiple vendors – including electronic data capture (EDC), clinical trial management systems (CTMS), safety systems, interactive voice response systems (IVRS), learning management systems (LMS) – easy-to-use user-interface and single-sign-on.
"The current complexity in how investigator sites communicate with study sponsors and clinical research organizations (CROs) make it difficult for all parties to track information and make timely decisions," said Kevin McNulty, director of product marketing for life sciences at Intralinks. "Deploying a single web-based clinical trial portal would enable sponsors and (CROs) to work faster, cut down on inefficiencies and help speed time to market."
The Intralinks Global Investigator Site Survey was conducted online by CenterWatch, a trusted source of clinical trials information for both professionals and patients. There were 551 responses to the survey with 76% of respondents based in North America, 17% in Europe, 5% in Asia Pacific and 2% in other areas. For more information on the survey, contact your Intralinks representative.
Intralinks Holdings, Inc. (NYSE: IL) is a leading, global technology provider of inter-enterprise content management and collaboration solutions. Through innovative Software-as-a-Service solutions, Intralinks solutions are designed to enable the exchange, control, and management of information between organizations securely and compliantly when working through the firewall. More than 2 million professionals at 800 of the Fortune 1000 companies depend on Intralinks' experience. With a track record of enabling high-stakes transactions and business collaborations valued at more than $19 trillion, Intralinks is a trusted provider of easy-to-use, enterprise strength, cloud-based collaboration solutions. For more information, visit www.Intralinks.com.
Forward Looking Statements
The forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are express or implied statements that are not based on historical information and include, among other things, statements concerning Intralinks' plans, intentions, expectations, projections, hopes, beliefs, objectives, goals and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control and could cause actual results to differ materially from those contemplated in these forward-looking statements. Accordingly, there can be no assurance that the results expressed, projected or implied by any forward-looking statements will be achieved, and readers are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements in this press release speak only as of the date hereof. As such, Intralinks undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For a detailed list of the factors and risks that could affect Intralinks' financial results, please refer to Intralinks' public filings with the Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K for the year-ended December 31, 2012. Intralinks undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Trademarks and Copyright
"Intralinks" and Intralinks' stylized logo are the registered trademarks of Intralinks, Inc. This press release may also refer to trade names and trademarks of other organizations without reference to their status as registered trademarks. © 2013 Intralinks, Inc. All rights reserved.
SOURCE Intralinks Holdings, Inc.